Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

This study is a Phase 1/2 trial testing a new experimental drug called MBRC-201 in people with advanced solid tumors that have not responded to standard treatments. The study will first find the right dose (Phase 1) and then test it in specific cancer types (Phase 2), including prostate cancer, lung cancer, breast cancer, colorectal cancer, and pancreatic cancer. **You may be eligible if...** - You are 18 years or older - You have a confirmed advanced solid tumor (specific types depending on the study phase) that has not responded to or has no remaining standard treatment options - Your general health status (ECOG) is 0–2 and expected survival is at least 3 months - Your blood counts, kidney, and liver function meet required levels **You may NOT be eligible if...** - You have had another cancer within the past 3 years (some exceptions apply) - You have active or uncontrolled brain or spinal fluid cancer involvement - You have active viral, bacterial, or fungal infections within 2 weeks before starting the drug - You have active hepatitis C, uncontrolled HIV, or active hepatitis B - You had a heart attack, stroke, or serious heart condition within the past 6 months - You have a prolonged heart rhythm (QTcF above 470 ms) - You have previously received an antibody-drug conjugate (ADC) with a specific payload type (for Phase 1b/2) - You received cancer treatment within 14 days before starting the study drug Talk to your doctor to see if this trial is right for you.